Rahul M. Kohli, M.D, Ph.D
Assistant Professor of Medicine
Department: Medicine
Graduate Group Affiliations
Contact information
502B Johnson Pavilion
Division of Infectious Disease, Department of Medicine
3610 Hamilton Walk
Philadelphia, PA 19104-6073
Division of Infectious Disease, Department of Medicine
3610 Hamilton Walk
Philadelphia, PA 19104-6073
Office: 215-573-7523
Fax: 215-349-5111
Fax: 215-349-5111
Email:
rkohli@upenn.edu
rkohli@upenn.edu
Publications
Education:
B.S. (Biochemistry)
University of Michigan, 1998.
M.D.
Harvard Medical School, 2004.
Ph.D. (Biochem & Mol Pharm, Advisor: Christopher T. Walsh)
Harvard Medical School, 2004.
Intern (Internal Medicine)
Hospital of the University of Pennsylvania, 2005.
Resident (Internal Medicine)
Hospital of the University of Pennsylvania, 2006.
Fellow (Pharm and Mol Science, Advisor: James T. Stivers)
Johns Hopkins University School of Medicine, 2010.
Fellow (Infectious Diseases)
Johns Hopkins Hospital, 2010.
Permanent linkB.S. (Biochemistry)
University of Michigan, 1998.
M.D.
Harvard Medical School, 2004.
Ph.D. (Biochem & Mol Pharm, Advisor: Christopher T. Walsh)
Harvard Medical School, 2004.
Intern (Internal Medicine)
Hospital of the University of Pennsylvania, 2005.
Resident (Internal Medicine)
Hospital of the University of Pennsylvania, 2006.
Fellow (Pharm and Mol Science, Advisor: James T. Stivers)
Johns Hopkins University School of Medicine, 2010.
Fellow (Infectious Diseases)
Johns Hopkins Hospital, 2010.
Description of Research Expertise
Our laboratory broadly focuses on DNA modifying enzymes and pathways, particularly those that contribute to genomic plasticity. We utilize a broad array of approaches, including biochemical characterization of enzyme mechanisms, chemical synthesis of enzyme probes, and biological assays spanning immunology and virology to study the fundamental question of how a genomic diversity arises in nature.Mutation and modification of the genome play an important role in several physiologically relevant areas and our areas of interest include:
1. Decipher the molecular basis for deamination by AID/APOBEC enzymes and perturb deaminase immunological functions
From the host immune perspective, the generation of genomic diversity is used as both a defensive and an offensive weapon. Host mutator enzymes such as Activation-Induced Cytidine Deaminase (AID) seed diversity in the adaptive immune system by introducing targeted mutations into the immunoglobulin locus that result in antibody maturation. Related deaminases of the innate immune system can directly attack retroviral threats by garbling the pathogen genome through mutation, as accomplished by the deaminase APOBEC3G, which restricts infection with HIV. Immune mutator enzymes, however, also pose a risk to the host, as overexpression or dysregulation have been associated with oncogenesis.
2. Explore the interplay of cytosine modifying enzymes on DNA demethylation
The singular genome is responsible for a wealth of different cell types, each of which can respond and adapt to environmental cues. In part, these epigenetic differences are linked to DNA modification. These modifications center around cytosine, where DNA deamination (AID/APOBEC enzymes) , oxidation (TET family enzymes) and methylation (DNMTs) can all interplay and tune the genome's potential. We are interested in the enzymatic activities of these cytosine modifying enzymes, particularly in the process of DNA demethylation which plays a role in embryogenesis, gene regulation and a potential pathological role in cancer.
3. Target pathogen pathways that promote evolution and resistance.
From the pathogen perspective, alteration in key antigenic determinants at a rate that outpaces immune responses is a potent means for evasion. Further, rapid mutation may allow for the development of resistance to antimicrobials. In bacteria, adaptation and evolution are closely linked to the stress response of SOS pathway. The SOS pathway can be triggered by numerous stressors, including antibiotics, and the net result is accelerated acquisition of drug resistance. We aim to characterize the key regulatory and effector enzymes from the SOS pathway and to target the pathway as a means to combat antibiotic resistance.
Our research program aims to understand these pathways of purposeful DNA modification and mutation. Additionally, we apply chemical biology to decipher and target these pathways, to impede the development of multidrug-resistance in pathogens or prevent the neoplastic transformations that can result from genomic mutation.
Selected Publications
Nabel CS, Jia H, Ye Y, Shen L, Goldschmidt HL, Stivers JT, Zhang Y, Kohli RM.: AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. Nature Chem Biol 8(9): 751-758, 2012.Nabel CS, Kohli RM: Demystifying DNA Demethylation. Science 333: 1229-1230, 2011.
Kohli RM: The Chemistry of a Dynamic Genome. Nature Chem Biol 6(12): 866-868, 2010.
Kohli RM, Maul RW, Guminski AF, McClure RL, Gajula KS, Saribasak H, McMahon MA, Siliciano RF, Gearhart PJ, Stivers JT.: Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J Biol Chem 285(52): 40956-40964, 2010.
Kohli RM, Abrams SR, Gajula KS, Maul RW, Gearhart PJ, Stivers JT: A portable hotspot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J Biol Chem 284: 22898-22904, 2009.
McMahon MA, Siliciano JD, Lai L, Liu JO, Stivers JT, Siliciano RF, Kohli RM: The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 283: 31289-31293, 2008.
Kohli RM, Burke MD, Tao J, Walsh CT: Chemoenzymatic route to macrocyclic hybrid peptide/polyketide-like molecules. J Am Chem Soc 125: 7160-7161, 2003.
Kohli RM, Walsh CT, Burkart MD: Biomimetic synthesis and optimization of cyclic peptide antibiotics. Nature 418: 658-661, 2002.
Kohli RM, Takagi J, Walsh CT: The thioesterase domain from a nonribosomal peptide synthetase as a cyclization catalyst for integrin binding peptides. Proc Natl Acad Sci USA 99: 1247-1252, 2002.
Trauger JW, Kohli RM, Mootz HD, Marahiel MA, Walsh CT: Peptide cyclization catalysed by the thioesterase domain of tyrocidine synthetase. Nature 407: 215-218, 2000.

